Lupin Q1 Profit Jumps 52% YoY to Rs 1,221 Crore, Sales Rise to Rs 6,164 Crore.

Lupin's Q1 profit rose 52% YoY to Rs 1,221 crore, driven by strong growth in the US and Indian markets. Sales increased to Rs 6,164 crore from Rs 5,514 crore in the year-ago period. The company's US sales grew 24% to Rs 2,404 crore. Lupin shares are in focus, with an average target price of Rs 2,230 and a 'Buy' rating from 37 analysts.

Lupin Limited, a prominent pharmaceutical company, reported a significant 52% year-on-year (YoY) growth in its consolidated profit after tax (PAT) for the June quarter, reaching Rs 1,221 crore. This robust performance was primarily driven by strong sales in both the United States and Indian markets. The company's total sales for the quarter stood at Rs 6,164 crore, up from Rs 5,514 crore in the year-ago period.

Notably, Lupin's US sales grew by 24% to Rs 2,404 crore, underscoring the company's strong presence and growth in the North American market. The company's Indian sales also contributed to the overall growth, reflecting the company's resilience and market penetration in its home market.

Lupin shares have been in the spotlight, with an average target price of Rs 2,230 and a 'Buy' rating from 37 analysts, indicating investor confidence in the company's future prospects. The stock's performance has been driven by the company's strategic focus on growth markets and its ability to maintain strong revenue growth.

References:
1. [1] https://www.etnownews.com/markets/stocks-to-watch-today-on-august-6-article-152416181
2. [2] https://www.moneycontrol.com/news/business/earnings/q1-results-2025-live-updates-bharti-airtel-adani-ports-britannia-lupin-berger-paints-bharti-hexacom-q1-earnings-august-5-liveblog-13390853.html